Design of the multicenter study of hydroxyurea in sickle cell anemia

Samuel Charache, Michael L. Terrin, Richard D. Moore, George J. Dover, Robert P. McMahon, Franca B. Barton, Myron Waclawiw, Susan V. Eckert

Research output: Contribution to journalArticlepeer-review

61 Scopus citations


The Multicenter Study of Hydroxyurea in Sickle Cell Anemia is a randomized double-blind placebo-controlled trial to test whether hydroxyurea can reduce the rate of painful crises in adult patients who have at least three painful crises per year. The sample size of 299 patients yields at least 90% power to detect a 50% or greater reduction in crisis rate. Dosage starts at 15 mg/kg/day and is titrated to the patient's maximum tolerated dose up to 35 mg/kg/day. Placebo dosage is titrated in similar fashion to maintain blinding. Attempts are made to ascertain medical contacts for at least 2 years after study entry. The Core Laboratory, Treatment Distribution Center, and Data Coordinating Center collaborate to provide standardized monitoring for toxicity and dose adjustments. The Core Laboratory also reduces the possibility of inadvertent unmasking of treatment assignment during review of hematologic data in clinical centers. An independent Crisis Review Committee classifies clinical events to assure that outcome evaluations are standardized and unbiased by knowledge of treatment assignments. The Data and Safety Monitoring Board assures scientific integrity of the study, as well as the safety and ethical treatment of study patients. We expect the study to determine whether or not treatment with hydroxyurea can offer significant clinical benefit to patients with the most common hereditary disorder among African-Americans in the United States.

Original languageEnglish (US)
Pages (from-to)432-446
Number of pages15
JournalControlled clinical trials
Issue number6
StatePublished - Dec 1995


  • fetal hemoglobin
  • hydroxyurea
  • sickle cell anemia
  • sickle cell crises prevention

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Design of the multicenter study of hydroxyurea in sickle cell anemia'. Together they form a unique fingerprint.

Cite this